RPTX News and Press, Repare Therapeutics Inc. From 11/23/20

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd...

Repare Therapeutics (RPTX): Q3 GAAP EPS of -$0.37 beats by $0.06.Cash and restricted cash of $348.1M.Press Release For further details see: Repare Therapeutics EPS beats by $0.06

– Initiated GLP toxicology studies for newly designated RP-6306, the Company’s CCNE-1 synthetic-lethal inhibitor program – Phase 1 clinical trial for RP-6306 is anticipated to commence in Q3 2021, reflecting an accelerated timeline from prior guidance ...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President ...

Repare Therapeutics (NASDAQ: RPTX ) : Q2 GAAP EPS of -$2.45 misses by $1.94 . More news on: Repare Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, a...